Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ICML 2019

Hodgkin Lymphoma

View all
1:46
Road ahead for immunotherapy in Hodgkin lymphoma: bispecifics & CAR-T
Stephen Ansell • 19 Jun 2019
2:01
Immune targeting of the microenvironment in classical Hodgkin lymphoma
Catherine Diefenbach • 19 Jun 2019

non-Hodgkin Lymphoma

View all
2:37
MabCute results: extended subcutaneous R maintenance for indolent NHL
Simon Rule • 19 Jun 2019
0:53
CAR-T horizons in NHL
Anna Sureda • 19 Jun 2019

CLL

View all
1:42
Moving towards chemo-free regimens in CLL
Michael Hallek • 19 Jun 2019
1:11
Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
Kerry Rogers • 19 Jun 2019

DLBCL

View all
2:59
Axi-cel in older patients: data from ZUMA-1 and clinical use
Sattva Neelapu • 19 Jun 2019
3:50
Updates in the management of CAR-T toxicities
Sattva Neelapu • 19 Jun 2019

MCL

View all
1:07
MCL trials to watch out for at ASH 2019
Simon Rule • 19 Jun 2019
0:55
Zanubrutinib in mantle cell lymphoma: updated safety and efficacy data
Constantine Tam • 20 Jun 2019

FL

View all
2:37
MabCute results: extended subcutaneous R maintenance for indolent NHL
Simon Rule • 19 Jun 2019
1:48
Zanubrutinib plus obinutuzumab: CLL, SLL & FL
Constantine Tam • 20 Jun 2019
The content of VJHemOnc is intended for healthcare professionals